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Abstract Cytokines are implied in polymyositis/derma-
tomyositis (PM/DM) pathogenesis. Our aim was to evalu-
ate the serum levels of interleukin-15 (IL-15), soluble
receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor
(sTNF-R1) in PM/DM patients and their relation to disease
activity and clinical symptoms. Thirty-eight patients who
met deﬁnite or probable criteria of Bohan and Peter for
DM/PM were included into the study. Results in patients
with active (41 observations) and inactive disease (24
observations) were compared with control (15 subjects).
The median level of IL-15 was 47.6 ± 170 pg/ml in active
patients, 25.15 ± 240 pg/ml in inactive and 28.5 ±
28.89 pg/ml in controls. We demonstrated signiﬁcant dif-
ferences between active patients and controls in levels of
IL-15 (0.016, 95%CI 1.39–57.1). The median level of sIL-
2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/
ml, and the median level of sTNF-R1 was 350 ± 388;
294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive
and control subjects, respectively. There were signiﬁcantly
higher serum levels of these cytokines in active patients
than in control subjects (for sIL-2R P = 0.05, CI95%
0.4–331; and sTNF-R1 P = 0.031, CI95% 15.1–321.5).
The interleukin levels did not differ between inactive
patients and controls. Elevation of IL-15, sIL2-R and
sTNF-R1 in active patients provides preliminary evidence
for the activation of inﬂammatory response during PM/DM
ﬂares. Further studies may be needed to explain the
mechanisms driving these diseases.
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Introduction
Interleukin-15 (IL-15) is a proinﬂammatory cytokine with
pleiotropic activity. It stimulates the proliferation and
activation of T cells, macrophages, CD5 memory lym-
phocytes and cytotoxic CD8 lymphocytes, proliferation of
myoblasts, endothelial cells and many others [1]. The IL-
15-speciﬁc receptor is composed of 3 subunits: alpha, beta
and gamma. The latter is shared with IL-2 and other
cytokines (IL-4, IL-7, IL-9 and IL-21), which explains their
similar effects. IL-15 seems to have the widest activity
spectrum of the whole IL-2 family. Both, IL-15 receptors
and IL-15 mRNA, were found in many non-immunological
tissues and cells (placenta, muscle, kidney, heart, ﬁbro-
blasts and myoblasts) [1].
Sugiura et al. published data that suggested that IL-15
plays a role in PM/DM pathogenesis. Increased production
of biologically active IL-15 was found in myoblasts col-
lected from patients with DM and PM [2]. Moreover,
increased serum cytokine level was found in 11 PM/DM
patients; however, no speciﬁc clinical data were given [3].
Our aim was to assess IL-15 levels in sera of PM/DM
patients in comparison with healthy controls.
At present, laboratory parameters related to disease
activity in PM/DM are still lacking. Potentially, serum
levels of IL-15 could help to quantify this activity. We
therefore determined the serum levels of IL-15 in DM/PM
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serum levels of soluble TNF-alpha type 1 receptor (sTNF-
R1) and soluble interleukin-2 receptor (sIL2-R) in order to
compare our group with data from earlier studies [4–6].
Materials and methods
Thirty-eight patients with deﬁnite or probable PM/DM,
according to criteria by Bohan and Peter, were included in
the study [7]. At study entry, we excluded all patients with
any inﬂammatory myopathy other than PM/DM or other
inﬂammatory disorder. Study procedures were performed
twice: at study entry (ﬁrst time-point) and 6–9 months later
(second time-point). Fifteen healthy subjects, matched for
age and sex, were the control group. At both time-points,
all patients were subjected to physical examination and
routine blood tests. Serum autoantibody assays were per-
formed at study entry. Other examinations were performed
if clinically indicated. Serum IL-15, sTNF-R1 and sIL2-R
were assessed using speciﬁc ELISAs. For IL-15, we used
antibodies produced by R&D System Inc. and standard IL-
15 from Genzyme Corporation. We used commercial kits
by BD Sciences for sTNF-R1 and kits by BioSource
Company for IL-2R. The sera were collected in the
morning between 7 and 9 a.m., in the fasting state.
Immediately after being centrifuged, the sera were frozen
at -70C.
Depending on disease activity, patients were allocated to
one of two groups, termed ‘‘active’’ and ‘‘remission’’,
respectively. Patients were deemed ‘‘active’’ in the pres-
ence of at least 1 of the following:
1. Active myositis. Judgment was based on clinical status
and preformed by one investigator (PM). New, wors-
ening or stable muscle weakness, with or without
myalgia, with elevation of muscle enzymes were
deﬁned as active myositis.
2. Active interstitial lung disease (ILD) deﬁned as
radiologically conﬁrmed interstitial changes (HRCT)
with the presence of ‘‘ground glass’’ opacities and/or
signiﬁcant worsening of DLCO since the last test.
3. Active skin lesions deﬁned as the presence of at least 1
of the following features: skin ulceration, erythro-
derma, erythema accompanied by vesiculobullous or
erosive lesions or necrosis, panniculitis, erythematous
rashes without secondary lesions, heliotrope rash,
Gottron’s papules or sign, periungual capillary
changes, alopecia or mechanic’s hands. Listed symp-
toms were assessed as active if they failed to improve
during the 4-week preceding examination.
4. Other clinically relevant features that were judged as
connected to disease activity. These included clinically
active polyarthritis, dysphagia, myocarditis, pericardi-
tis, gastrointestinal ulceration and fever.
IL-15, sTNF-R1 and sIL-2 levels were compared
between the two patient groups as well as between
‘‘active’’ patients and controls and between ‘‘remission’’
patients and controls. In patients examined twice, we
assessed the change in cytokine levels and their relation-
ship with the clinical status and laboratory parameters.
The statistical signiﬁcance of differences in IL-15,
sTNF-R1 and sIL2-R levels between patient groups and
control subjects was analysed using the Student’s t-test
when the group’s data had normal distribution and similar
variance or the Wilcoxon test when these conditions were
not met. Multiple regression analysis was performed to
identify potential correlation between cytokine levels and
clinical data.
The study was approved by the local Ethical Committee.
All subjects provided informed consent before any study
procedure.
Results
There were no signiﬁcant differences in demographic sta-
tus between the patient and control groups (Table 1).
Clinical features are gathered in Table 2.
The most common symptom was muscle weakness with
the elevation of CK. ILD was the most frequent internal
organ involvement. Antinuclear antibodies (ANA) were
positive in 29 patients (55.6%), anti-Jo-1 antibodies in 9
(23.6%) at the ﬁrst time-point of study. Before study entry,
65.7% of patients were medically treated, glucocorticos-
teroids (GCS) being most frequently used medication
(65.7%). Median GCS dose was 11 mg and treatment
median time before the ﬁrst study time-point was
2.5 months. At the ﬁrst time-point, 6 patients were treated
with cyclophosphamide (CYC), 5 with azathioprine (AZA)
and 3 with methotrexate (MTX). At the second evaluation,
almost all patients were treated (96.8%) again mainly with
GCS (96.8%, median dose 15 mg, median treatment
duration 28 months). Other treatments included MTX
(7%), cyclosporin A (CsA, 22%), CYC (19%) and chlo-
roquine (7%).
Table 1 Demographic data of the patient and control groups
Patients Controls P
Gender (F/M) 21/17 8/7 NS
Age 53 ± 13.5 44 ± 14.8 NS
Disease duration (months) 12 ± 60 NA NA
P statistics for the comparison between patients and controls
NS non-signiﬁcant, NA not applicable
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matory myopathies were exclusionary, three patients had
been diagnosed with malignant tumours during the study
and eventually diagnosed with cancer-induced DM. Four
patients died during the observation: two due to cancer, one
due to cardiomyositis related to PM and one due to heart
and lung failure caused by ILD.
Overall, we assessed 27 patients twice and 11 once.
The absence of the second assessment resulted from the
following causes: death in four cases; loss from follow-
up in seven cases (2 moved to another region of the
country, 5 could not come within projected timelines). In
our group, 30 patients (78.9%) were assessed as active at
the ﬁrst time-point and 11 (40.7%) at the second.
Together, we made 41 assessments in active disease and
24 in inactive. The proportion of patients with PM to
patients with DM in both groups was similar (45% vs.
50%, NS).
IL-15 levels were signiﬁcantly higher in the whole
patient group in comparison with the control group at the
ﬁrst time-point of the study (Table 3). Median values were
45 ± 188.02 pg/ml versus 28.5 ± 28.89 pg/ml in control
(P = 0.038). Median for summarized results in patients’
group was 43.8 ± 205.14 and was signiﬁcantly higher than
in control (P = 0.05, 95%CI 20–126).
The median level of IL-15 was twice as high in active
comparing to inactive patients, but difference was not
statistically signiﬁcant. The median level in active group
was signiﬁcantly higher (P = 0.016) than in control group
(Table 4).
We identiﬁed no speciﬁc clinical feature related to
higher IL-15 levels. Previous treatment also had no impact
on IL-15 levels.
At study entry, sIL2-R concentration was signiﬁcantly
higher (P = 0.027) in the patient group in comparison with
controls. This was not found at the second time-point.
The sTNF-R1 and sIL2-R levels, as well as IL-15 levels,
were signiﬁcantly higher in active subjects than in controls
(P\0.05, P = 0.031, P = 0.016, respectively; Table 4).
The sTNF-R1 median was higher in patients with malig-
nancies(1,017 pg/ml)thaninotherpatients(327 pg/ml)and
signiﬁcantly higher than in the control group (P = 0.04).
The levels of sTNF-R1 and sIL2-R were not related to any
clinical symptoms, laboratory results or treatment.
Median levels of IL-15, sIL2-R and sTNF-R1 in patients
who died were not signiﬁcantly different from whole
group, active patients, non-active patients or controls and
were 32.1, 266.7 and 417.3 pg/l, respectively.
Discussion
The role of IL-15 in the pathogenesis of inﬂammatory,
autoimmune disease like rheumatoid arthritis has been
demonstrated, but data explaining the role of IL-15 in the
pathogenesis of PM/DM are limited [8–10].
IL-15 seems to be the ideal candidate for the factor
sustaining the inﬂammation in these rare diseases, as it is
not only produced by myoblasts, but also its receptor has
been found in muscle tissue [1]. The increased synthesis of
IL-15 by myoblasts isolated from PM/DM patients, but not
from healthy controls, was shown by Siagura et al. [2].
In the present report, we conﬁrm the existence of higher
levels of IL-15 in PM/DM patients compared to healthy
controls as was previously reported by Suzuki et al. [3]
Table 2 Clinical features in examined group
Study point 1st (n = 38) 2nd (n = 27)
Muscle weakness 30 (78.8%) 16 (59.2%)
Myalgia 11 (28.9%) 1 (3.7%)
Fever 4 (10.5%) 0
ILD 16 (42.1%) 9 (33.3%)
Dysphagia 5 (13.1%) 4 (14.8%)
Dysphonia 4 (10.5%) 0
Cardiac involvement 2 (5.3%) 0
Arthritis 8 (21%) 1 (3.7%)
Gottron’s sign 9 (23.7%) 4 (14.8%)
Heliotrope 12 (31.6%) 8 (29.6%)
Periungual changes 9 (23.7%) 1 (3.7%)
Skin ulcers 2 (5.3%) 1 (3.7%)
Other erythemas 8 (21.1%) 7 (25.9%)
Mechanic’s hands 4 (10.5%) 2 (7.4%)
Oedema 1 (2.6%) 0
Livedo reticularis 4 (10.5%) 3 (11.1%)
Raynaud’s phenomenon 4 (10.5%) 3 (11.1%)
Active skin changes 19 (50%) 17 (62.9%)
Active subjects 30 (78.9%) 11 (40.7%)
Number of patients with present feature
Table 3 IL15, sIL2-R and sTNF-R1 levels in PM/DM patients (in
the ﬁrst and second study time-point) and in control group
Median (pg/ml) P versus control/95% CI
IL-15 at 1st point 45 ± 188.02 0.038/17.8–47.4
IL-15 2nd point 28.53 ± 222.76 0.15/0.017–48.7
IL-15 control 28.5 ± 28.89 NA
sIL-2R at 1st point 317.2 ± 335.8 0.027/4.9–345
sIL-2R 2nd point 159.9 ± 563.8 0.4/0.001–231
sIL-2R control 144.3 ± 152.9 NA
sTNF-R1 at 1st point 328.8 ± 647.7 0.067/(-11)–286.5
sTNF-R1 2nd point 367.9 ± 724.0 0.041/9.81–213.9
sTNF-R1 control 205.9 ± 629.6 NA
Median level and standard deviation.Pand 95%CI between patients
and controls
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and IL-15 serum concentration. Not all measured param-
eters achieved statistical signiﬁcance, possibly due to the
relatively small number of patients included in our study.
Suzuki et al. found higher levels of IL-15 in patients with
various inﬂammatory connective tissue diseases and ILD
[3]. We did not demonstrate a similar phenomenon in our
group, but our study selected only PM/DM patients with
the possible domination of muscle IL-15 production. Our
results add to previous observations and give further evi-
dence in favour of a stimulating role of IL-15 in these
diseases.
We noted higher levels of sTNF-R1 and sIL2-R in the
patients in active disease. High sIL2-R levels have been
found in many inﬂammatory and neoplasmatic conditions,
often correlating with disease activity and determining
prognosis [4, 10–13]. We demonstrated a correlation
between sIL2-R levels and disease activity, but not with
any speciﬁc clinical parameter. Samsonov et al. [4] failed
to notice any correlation between myositis activity and
serum concentrations of sIL2-R; however, they did ﬁnd
such an association with ESR.
Our results of sTNF-R1 levels are consistent with pre-
vious reports [5, 6]. Other authors found correlation with
disease activity not only for sTNF-R1 but also for sTNF-R2
[6]. Extremely high levels of the receptor found in subjects
with neoplasm-induced DM are interesting but due to the
small number of patients and possible biases, no ﬁrm
conclusions can be drawn. However, since high levels of
sTNF-R1 were observed in cancer patients without
inﬂammatory myopathies, it is not clear whether this
parameter can be used as a differentiating factor between
primary DM and cancer-induced DM [14–18].
Conclusion
High concentration of IL-15 as well as sIL2-R and sTNF-
R1 in active patients with DM/PM provides additional
evidence for a broad activation of inﬂammatory response.
Further studies are needed to explain the mechanisms
driving these diseases. High level sTNF-R1 in cases of
neoplasm-induced PM/DM requires conﬁrmation in the
future studies.
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